The stock has been moving up since the beginning of the month, so it may have a little pullback now that the earnings beat is out of the bag.
4:34 pm Tenet Healthcare beats by $0.12, beats on revs (THC): Reports Q4 (Dec) earnings of $0.43 per share, excludingnon-recurring items, $0.12 better thanthe Capital IQ Consensus Estimate of $0.31; revenues rose 67.2%year/year to $4.23 bln vs the $4.16 bln consensus.
Making things easier
Although Twitter has millions and millions of extremely active users, the service can cause head-scratching among those who don't understand how it works. Costolo said that the company is putting much of its energy this year into solving that problem.
Already, it has made moves like unveiling a "media forward" strategy that front-loads many tweets with things like photographs and video. In addition, it has been working to improve things like conversation flow, so that users see more threaded discussions than simple chronological feeds. On the whole, though, Twitter works well, Costolo argued, and the changes it must make are hardly fundamental. "We don't think we need to change anything about the core characteristics of our platform," he said. "We just need to make Twitter a better Twitter."
From Blau's perspective, that was a key point. "One of the best things I heard [during the call] was the plans for changing the user experience," Blau said. "Not moving away from the core product, but making it a lot more accessible to users."
One thing Costolo was clear about was that Twitter must make it simple for new people to join and begin using the service on mobile devices. In its earnings report, Twitter said that 76 percent of its monthly active users were on mobile, highlighting the importance of making the mobile Twitter experience as good as, if not better, than on desktop computers.
Then again, Twitter has been constantly refining its user experience across all devices to be consistent, and to be geared toward an easy mobile experience. It also has one structural advantage over Facebook in that its ability to display ads on mobile devices is essentially the same as on desktop computers.
It's better to keep you mouth shut and let people think your a fool then to open your mouth and remove all doubt.
How do they circumvent the fact that droxidopa has been approved in Japan since 1989, and again in 2000 for a Vertigo remedy. Do you just say that the Japanese don't have a clue and no track record. Or do you say that my FDA panel voted 7-4 in favor the first time and now 16-1 in favor and I will put my faith in their recommendation. I think I would go with my panel's decision, otherwise I would look the fool.
Droxidopa aka Northera has been available in Japan since 1989. CHTP just got an FDA panel approval vote 16-1 in favor of Northera. I can't imagine the FDA going against its own Panel twice, especially when this drug has been approved in Japan for years and was approved as a Vertigo remedy in 2000 by the Japanese as well.
Droxidopa aka Northera, was approved in Japan in 1989 fir the treatment of orthostatic hypotension in familial amyloid polyneuropathy and Shy-Drager Syndrome (SDS, now known as MSA, multiple system atrophy) and for the relief of frozen gait or dizziness upon standing up associated with Parkinson's disease. It was also approved in Japan in 2000 for the alleviation of vertigo, staggering, dizziness on standing up, lassitude, and weakness in hemodialytic patients with orthostatic hypotension. this product has not been marketed in the U.S. It should be noted that the clinincal experience in Japan SUPPORTS INDIVIDUALIZED TREATMENT WITH DROXIDOPA.
Droxidopa aka Northera has been a treatment in Japan since 1989 and shows no major fatalaties in rhesus monkeys and dogs.
I forgot to also include Wedbush who thinks the fair value is also $8 and think the shares will double with approval
Ladenburg target is $7 JMP securities Target is $12 Needham target is $8 the AVERAGE TARGET is $9 if you include Stephen Simpson, of the Motley Fool's Target of $5.65 then the AVERAGE TARGET becomes $8.16
I say that if the FDA does not listen to the advice of it's panel on CHTP after the panel voted 16-1 in favor, then the fools are the FDA, and need to dis ban the panel all together. I believe, that a favorable outcome for CHTP is in the card. The FDA, would not want to come out with egg on their faces, and look like fools, for not giving approval after their own panel voted 16-1 in favor.
All the fortune tellers out there who say there is no risk either are blind or have their heads up there butts. This stock sold off with a nice SMACK DOWN after the open, probably by profit takers, and those on the inside know. And they may not be finished. Probably try to take this down some more, before any meaningful rebound. The stock moved down so fast that the deer in headlights did not have a chance to sell the weak hands. So I think another round of hard selling will get those out tomorrow.